Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM6A | O15550 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10480769 | 0.85 | KDM4E (0.42) | KDM4EHTTCYP2D6TP53SMN1; SMN2 | |
| SCHEMBL958138 | 0.81 | KDM4E (0.55) | KDM4EHTTCYP2D6TP53SMN1; SMN2 | |
| SCHEMBL3319649 | 0.80 | APP (0.37) | KDM4EHTTCYP2D6TP53SMN1; SMN2 | |
| SCHEMBL9386569 | 0.79 | KDM4E (0.39) | KDM4EHTTCYP2D6TP53SMN1; SMN2 | |
| SCHEMBL3316508 | 0.78 | KDM4E (0.34) | KDM4EHTTCYP2D6TP53SMN1; SMN2 | |
| SCHEMBL9748019 | 0.73 | GABRA1 (0.33) | KMT2AGABRA1GABRB2MEN1 | |
| SCHEMBL9748012 | 0.69 | ALDH1A1 (0.40) | NPC1KMT2ARAB9AMEN1LMNA | |
| SCHEMBL9651154 | 0.69 | ALDH1A1 (0.39) | HTTCYP2D6SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL7109188 | 0.66 | NPC1 (0.43) | KDM4ENPC1KMT2ARAB9AMEN1 | |
| SCHEMBL3651867 | 0.66 | NPC1 (0.37) | KDM4ECYP2D6NPC1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1989009211-A1 | PROCESS FOR PRODUCING PYRID-4-ONES | THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) | 1989-10-05 | — | — | WO | claimed |
| EP-0335745-A1 | Process for producing pyrid-4-ones | THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) | 1989-10-04 | — | — | EP | claimed |
| US-20120077852-A1 | HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS | CARLO GHISALBERTI (BR) | 2012-03-29 | — | — | US | disclosed |
| EP-1567156-B1 | HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS | RELIVIA SRL (IT) | 2009-08-26 | — | — | EP | disclosed |
| US-20060135448-A1 | Hydroxypyridinones for the local treatment of skin microcirculatroy disorders | RELIVIA S.R.L. (IT) | 2006-06-22 | — | — | US | disclosed |
| EP-1567156-A2 | HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS | RELIVIA SRL (IT) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004045609-A2 | HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS | RELIVIA SRL (IT) | 2004-06-03 | — | — | WO | disclosed |
| WO-1989009211-A1 | PROCESS FOR PRODUCING PYRID-4-ONES | THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) | 1989-10-05 | — | — | WO | disclosed |
| EP-0335745-A1 | Process for producing pyrid-4-ones | THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077852-A1 | HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS | HPGD, HPGDS, MVD | KDM4E 1268/4885HTT 3286/4885CYP2D6 1161/4885 |
| US-20060135448-A1 | Hydroxypyridinones for the local treatment of skin microcirculatroy disorders | HPGD, MVD, HPGDS | KDM4E 1203/4885HTT 3249/4885CYP2D6 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.